Biogen (BIIB) announced that dosing has begun in a phase III study evaluating its key pipeline candidate, felzartamab, in adult kidney transplant recipients diagnosed with late antibody-mediated rejection (AMR).AMR is a leading cause of kidney transplant failure. AMR occurs in kidney transplant recipients when the antibodies of the immune system attack the transplanted kidney, causing damage to the kidney tissue.The   52-week, double-blind, placebo-controlled, multicenter, randomized TRANSCEND phase III stu ...